Reach Us +44-1647-403003
Biomarker Development For Allergic Risk Assessment | 60841
ISSN: 2471-8556

Oncology & Cancer Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Biomarker development for allergic risk assessment


Ying Mu

Center for Devices and Radiological Health-US FDA, USA

Keynote: Oncol Cancer Case Rep

DOI: 10.4172/2471-8556.C1.001

There is an increase in the incidence of allergy/immunotoxicity-related post-market adverse events associated with medical devices. Biomarkers are commonly used in toxicology for risk assessment and clinically as diagnostic and monitoring tests. We developed a new in vitro model where human peripheral blood mononuclear cells (PBMC) serve as immunomodulators for biomarker development specifically for metal related allergenicity. The cell surface proteins were determined quantitatively. One of the purposes is to know whether the biomodulator system is transferable from the dendritic cell (DC) to the PBMC. Out of 12 surface proteins selected from the first tier selection that were screened, we found consistency of BM1 performance between DC and PBMC, and other 3 proteins (BM2, BM3 and BM4) showed promise. The expression of BM1 was downregulated significantly following exposure to three well-known metallic allergens (Cobalt (II) chloride, nickel (II) sulfate, potassium dichromate (VI)), while the expression remained unchanged when exposed to two metallic nonallergens (lead (IV) acetate, magnesium (II) chloride) compared to untreated cells. Data from four healthy donors showed the same pattern. These results indicate that BM1 shows promise for use as a pre-clinical biomarker in screening potential allergenic risks to metalcontaining devices. Further validation is planned.

Mu has completed his PhD from Gunma University/Japan and postdoctoral studies at Kyoto University, Carnegie Mellon University and University of Pittsburgh. He is the board certified toxicologist (D.A.B.T.) and a principal investigate at the FDA. He has published more than 25 papers in reputed journals and is interested in the development of biomarkers for allergic risk assessment.

Email: [email protected]

Relevant Topics